Cargando…
Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans
BACKGROUND: Glutamate transmission is implicated in drug-induced behavioural sensitization and the associated long-lasting increases in mesolimbic output. Metabotropic glutamate type 5 (mGlu5) receptors might be particularly important, but most details are poorly understood. METHODS: We first assess...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Joule Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955855/ https://www.ncbi.nlm.nih.gov/pubmed/32559027 http://dx.doi.org/10.1503/jpn.190162 |
_version_ | 1783664328616968192 |
---|---|
author | Smart, Kelly Nagano-Saito, Atsuko Milella, Michele S. Sakae, Diana Yae Favier, Mathieu Vigneault, Erika Louie, Leanne Hamilton, Alison Ferguson, Stephen S.G. Rosa-Neto, Pedro Narayanan, Sridar Mestikawy, Salah El Leyton, Marco Benkelfat, Chawki |
author_facet | Smart, Kelly Nagano-Saito, Atsuko Milella, Michele S. Sakae, Diana Yae Favier, Mathieu Vigneault, Erika Louie, Leanne Hamilton, Alison Ferguson, Stephen S.G. Rosa-Neto, Pedro Narayanan, Sridar Mestikawy, Salah El Leyton, Marco Benkelfat, Chawki |
author_sort | Smart, Kelly |
collection | PubMed |
description | BACKGROUND: Glutamate transmission is implicated in drug-induced behavioural sensitization and the associated long-lasting increases in mesolimbic output. Metabotropic glutamate type 5 (mGlu5) receptors might be particularly important, but most details are poorly understood. METHODS: We first assessed in mice (n = 51, all male) the effects of repeated dextroamphetamine administration (2.0 mg/kg, i.p.) on locomotor activity and binding of the mGlu5 ligand [(3)H]ABP688. In a parallel study, in 19 stimulant-drug-naïve healthy human volunteers (14 female) we administered 3 doses of dextroamphetamine (0.3 mg/kg, p.o.) or placebo, followed by a fourth dose 2 weeks later. We measured [(11)C]ABP688 binding using positron emission tomography before and after the induction phase. We assessed psychomotor and behavioural sensitization using speech rate, eye blink rate and self-report. We measured the localization of mGlu5 relative to synaptic markers in mouse striatum using immunofluorescence. RESULTS: We observed amphetamine-induced psychomotor sensitization in mice and humans. We did not see group differences in mGlu5 availability following 3 pre-challenge amphetamine doses, but group differences did develop in mice administered 5 doses. In mice and humans, individual differences in mGlu5 binding after repeated amphetamine administration were negatively correlated with the extent of behavioural sensitization. In drug-naïve mice, mGlu5 was expressed at 67% of excitatory synapses on dendrites of striatal medium spiny neurons. LIMITATIONS: Correlational results should be interpreted as suggestive because of the limited sample size. We did not assess sex differences. CONCLUSION: Together, these results suggest that changes in mGlu5 availability are not part of the earliest neural adaptations in stimulant-induced behavioural sensitization, but low mGlu5 binding might identify a higher propensity for sensitization. |
format | Online Article Text |
id | pubmed-7955855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Joule Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79558552021-03-19 Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans Smart, Kelly Nagano-Saito, Atsuko Milella, Michele S. Sakae, Diana Yae Favier, Mathieu Vigneault, Erika Louie, Leanne Hamilton, Alison Ferguson, Stephen S.G. Rosa-Neto, Pedro Narayanan, Sridar Mestikawy, Salah El Leyton, Marco Benkelfat, Chawki J Psychiatry Neurosci Research Paper BACKGROUND: Glutamate transmission is implicated in drug-induced behavioural sensitization and the associated long-lasting increases in mesolimbic output. Metabotropic glutamate type 5 (mGlu5) receptors might be particularly important, but most details are poorly understood. METHODS: We first assessed in mice (n = 51, all male) the effects of repeated dextroamphetamine administration (2.0 mg/kg, i.p.) on locomotor activity and binding of the mGlu5 ligand [(3)H]ABP688. In a parallel study, in 19 stimulant-drug-naïve healthy human volunteers (14 female) we administered 3 doses of dextroamphetamine (0.3 mg/kg, p.o.) or placebo, followed by a fourth dose 2 weeks later. We measured [(11)C]ABP688 binding using positron emission tomography before and after the induction phase. We assessed psychomotor and behavioural sensitization using speech rate, eye blink rate and self-report. We measured the localization of mGlu5 relative to synaptic markers in mouse striatum using immunofluorescence. RESULTS: We observed amphetamine-induced psychomotor sensitization in mice and humans. We did not see group differences in mGlu5 availability following 3 pre-challenge amphetamine doses, but group differences did develop in mice administered 5 doses. In mice and humans, individual differences in mGlu5 binding after repeated amphetamine administration were negatively correlated with the extent of behavioural sensitization. In drug-naïve mice, mGlu5 was expressed at 67% of excitatory synapses on dendrites of striatal medium spiny neurons. LIMITATIONS: Correlational results should be interpreted as suggestive because of the limited sample size. We did not assess sex differences. CONCLUSION: Together, these results suggest that changes in mGlu5 availability are not part of the earliest neural adaptations in stimulant-induced behavioural sensitization, but low mGlu5 binding might identify a higher propensity for sensitization. Joule Inc. 2021-01 2020-06-19 /pmc/articles/PMC7955855/ /pubmed/32559027 http://dx.doi.org/10.1503/jpn.190162 Text en © 2021 Joule Inc. or its licensors This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e. research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Research Paper Smart, Kelly Nagano-Saito, Atsuko Milella, Michele S. Sakae, Diana Yae Favier, Mathieu Vigneault, Erika Louie, Leanne Hamilton, Alison Ferguson, Stephen S.G. Rosa-Neto, Pedro Narayanan, Sridar Mestikawy, Salah El Leyton, Marco Benkelfat, Chawki Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans |
title | Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans |
title_full | Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans |
title_fullStr | Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans |
title_full_unstemmed | Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans |
title_short | Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans |
title_sort | metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955855/ https://www.ncbi.nlm.nih.gov/pubmed/32559027 http://dx.doi.org/10.1503/jpn.190162 |
work_keys_str_mv | AT smartkelly metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT naganosaitoatsuko metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT milellamicheles metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT sakaedianayae metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT faviermathieu metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT vigneaulterika metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT louieleanne metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT hamiltonalison metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT fergusonstephensg metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT rosanetopedro metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT narayanansridar metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT mestikawysalahel metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT leytonmarco metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans AT benkelfatchawki metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans |